Microsomal prostaglandin E synthase 2 deficiency is resistant to acetaminophen-induced liver injury
Acetaminophen (APAP)-induced liver injury is the main cause of acute liver failure. This study investigated the role of microsomal prostaglandin E synthase 2 (mPGES-2), discovered as one of the prostaglandin E2 (PGE2) synthases, in mediating APAP-induced liver injury. Using mPGES-2 wild-type (WT) and knockout (KO) mice, marked resistance to APAP-induced liver damage was found in mPGES-2 KO, as indicated by robust improvement of liver histology, changes in liver enzyme release, and marked decrease in APAP–cysteine adducts (APAP–CYS) and inflammatory markers. Moreover, the results confirmed that increase in liver PGE2 content in KO mice under basal conditions was not critical for the protection from APAP-induced liver injury. Importantly, mPGES-2 deletion inhibited the production of malondialdehyde (MDA), increasing glutathione (GSH) level. Enhanced GSH level may contribute to the inhibition of APAP toxicity in mPGES-2 KO mice. To further elucidate the role of mPGES-2 in the liver injury induced by APAP, adeno-associated viruses (AAV) were used to overexpress mPGES-2 in the liver. The results showed that mPGES-2 overexpression aggravates liver injury associated with an increase in inflammatory markers and chemokines after APAP treatment. Moreover, a lower level of GSH was detected in the mPGES-2 overexpression group compared to the control group. Collectively, our findings indicate that mPGES-2 plays a critical role in regulating APAP-induced liver injury, possibly by regulating GSH and APAP–CYS level, which may provide a potential therapeutic strategy for the prevention and treatment of APAP-induced liver injury.
KeywordsMicrosomal prostaglandin E synthase 2 Acetaminophen Liver injury Prostaglandin E2 Glutathione
C–X–C motif chemokine ligand
C–X–C chemokine receptor
16,16-Dimethyl prostaglandin E2
Microsomal prostaglandin E synthase 2
Tumor necrosis factor
Monocyte chemoattractant protein-1
NLR family pyrin domain containing 3
This work was supported by the National Natural Science Foundation of China (Grant no. 81603179), the China Postdoctoral Science Foundation (Grant no. 2016M601893), the China Postdoctoral Science Special Foundation (Grant no. 2018T110555), Top-notch Academic Programs Project of Jiangsu Higher Education Institutions (PPZY2015B161) and Innovative Entrepreneurship Training Program for National College Students (Grant no. 201710313022).
Y Sun and XX Yin conducted the study concept and design. H Wang, RM Zhang, and YY Zhu contributed to data acquisition, data analysis, and drafting of the manuscript. T Teng, YJ Cheng, A Chowdhury, JH Lu, ZJ Jia, and J Song participated critically in the discussion and revision of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures in this study were carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of China Association for Laboratory Animal Science and approved by the Animal Ethics Committee of Xuzhou Medical University.
- Bhave VS, Donthamsetty S, Latendresse JR, Cunningham ML, Mehendale HM (2011) Secretory phospholipase A(2)-mediated progression of hepatotoxicity initiated by acetaminophen is exacerbated in the absence of hepatic COX-2. Toxicol Appl Pharmacol 251(3):173–180. https://doi.org/10.1016/j.taap.2011.01.013 CrossRefPubMedGoogle Scholar
- Greco A, Ajmone-Cat MA, Nicolini A, Sciulli MG, Minghetti L (2003) Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase. J Neurosci Res 71(6):844–852. https://doi.org/10.1002/jnr.10543 CrossRefPubMedGoogle Scholar
- James LP, Kurten RC, Lamps LW, McCullough S, Hinson JA (2005) Tumour necrosis factor receptor 1 and hepatocyte regeneration in acetaminophen toxicity: a kinetic study of proliferating cell nuclear antigen and cytokine expression. Basic Clin Pharmacol Toxicol 97(1):8–14. https://doi.org/10.1111/j.1742-7843.2005.pto_02.x CrossRefPubMedGoogle Scholar
- Jania LA, Chandrasekharan S, Backlund MG et al (2009) Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis. Prostaglandins Other Lipid Mediat 88(3–4):73–81. https://doi.org/10.1016/j.prostaglandins.2008.10.003 CrossRefPubMedGoogle Scholar
- Qiu Y, Benet LZ, Burlingame AL (2001) Identification of hepatic protein targets of the reactive metabolites of the non-hepatotoxic regioisomer of acetaminophen, 3′-hydroxyacetanilide, in the mouse in vivo using two-dimensional gel electrophoresis and mass spectrometry. Adv Exp Med Biol 500:663–673CrossRefGoogle Scholar
- Takusagawa F (2013) Microsomal prostaglandin E synthase type 2 (mPGES2) is a glutathione-dependent heme protein, and dithiothreitol dissociates the bound heme to produce active prostaglandin E2 synthase in vitro. J Biol Chem 288(14):10166–10175. https://doi.org/10.1074/jbc.M112.418475 CrossRefPubMedPubMedCentralGoogle Scholar
- Yang B, Gao X, Ren Y, Wang Y, Zhang Q (2016) Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and therapeutic medicine 12(4):2531–2536. https://doi.org/10.3892/etm.2016.3676 CrossRefPubMedPubMedCentralGoogle Scholar